Contribution of a heparin-binding haemagglutinin interferon-gamma release assay to the detection of Mycobacterium tuberculosis infection in HIV-infected patients: comparison with the tuberculin skin test and the QuantiFERON®-TB Gold In-tube
Chloé Wyndham-Thomas(Université Libre de Bruxelles), Françoise Mascart(Université Libre de Bruxelles), Marc Hildebrand(Hôpitaux Iris Sud), F. Domont(Sorbonne Université), Charlotte Martin(Centre Hospitalier Universitaire de Saint-Pierre), Jean‐Christophe Goffard(Université Libre de Bruxelles), Marc Loyens(Centre National de la Recherche Scientifique), Jean‐Paul Van Vooren(Université Libre de Bruxelles), Myriam Libin(Université Libre de Bruxelles), Camille Locht(Centre National de la Recherche Scientifique), Kinda Schepers(Délégation Paris 5), Violette Dirix(Université Libre de Bruxelles)
Cited by 15
Related Papers
First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020
|Eurosurveillance|2020|715
Immunogenicity and protective efficacy of a tuberculosis DNA vaccine
|Nature Medicine|1996|632
The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination
|Nature|2001|464
Deep Dermatophytosis and Inherited CARD9 Deficiency
|New England Journal of Medicine|2013|403
Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients
|Critical Care|2020|302